Biological pathways are the crucial biological mechanisms in living cells. The huge volume of genomics and proteomics data requires computational methods for predicting or reconstructing pathways. Thus, the application of protein-protein interaction (PPI) or gene expression methods is insufficient to discover meaningful pathways. The integration of PPIs and gene profiles is a better approach to uncover the regulation of pathway and must be utilized well. Previous studies on this topic only focus on the gene level or some limited local groups. This study presents an approach to finding potential fragments of active pathways around known pathways between the various stages of diseases. The proposed method used a maximum score-based function that integrates genomics and proteomics information. This method quantified the strength of gene expression change and the degree of protein-protein interactions to illustrate global status as pathway maps. In this study, we use prostate cancer data as an example to explain which potential fragments of pathway co-constructed a pathway map of prostate cancer at different disease statuses. The resulting map shows a possible correspondence between known pathway and cancer-related genes that are not on the known pathway. Comparing distinct status pathway map reveals a global change of different disease states pathway level. The pathway map of different disease statuses can provide more insight in the progress of cancer.
Introduction
Bioinformatics has benefitted greatly from advances in computer science and biology laboratory techniques, an era of rapid accumulation of genomic and proteomic information. For example, the Gene Expression Omnibus (GEO) is one of several public genomic data repositories [1] . The GEO includes 12,211 platforms, 1,024,125 samples, 42,673 series and 3,413 datasets. Computational biology methods can help researchers obtain a better understanding of complex systems (e.g., protein-protein interaction network, regulatory pathways or cancer mechanisms). A signal transduction pathway is a main respondence for extracellular excitement. When signal pathways are involved in activating apoptosis, cell cycle, or proliferation, they have a comprehensive effect on upstream/downstream relationships between interacting proteins/genes. The widely used pathway database is the Kyoto Encyclopedia of Genes and Genomes (KEGG). The KEGG is a database that integrates genomic, chemical, and systemic functional information [2] . The KEGG currently includes 275,060 pathways. Researchers can access these online resources easily through their web-based interface. Early pathway prediction methods, such as PathFinder, were based only on PPIs. PathFinder is a tool for finding potential pathways [3] that maps GO annotations onto the PPI network and applies the association rule method to identify pathways with high confidence. The recall rate is 78% and precision rate is 40%. When researchers investigate the importance of gene regulation, they often used PPIs and gene expression data to reconstruct some simple signaling networks [4] [5] [6] . One method, NetSearch, tried to integrate PPI and gene expression [4] . This approach used gene expression data to cluster proteins and scored protein by clustering, and was capable of reconstructing MAPK signal pathways. The recall rate for this approach is 44%, with a precision rate of 24%. Ruth et al. built PathwayOracle Toolkit. This toolkit applies the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) method [7] to score PPI data, and then adopts Eppstein's k-shortest algorithm is used for pathway prediction [8] . Some of the methods mentioned above only use PPI, which does not sufficiently represent the entire pathway, and some are limited to reconstructing specific species. Even approaches that consider gene-level data only apply that data for clustering, and fail to exhibit true gene expression values. Researchers have recently identified many disease markers by analyzing genome-wide and proteomic-wide information. However, investigators have shown that many well-known risk factors may be partial emphases rather than global mechanisms of disease. To identify a marker for more complete performance of disease is a challenging. A subnetwork marker is more reproducible than individual marker genes selected without network information [9] . Most previous methods cannot identify molecular changes and relationships on the environmental side.
In the past researches of prostate cancer, Yu et al. tested a comprehensive gene expression analysis on 152 human samples and compared with normal neighbouring prostate tissues to confirm an alteration of gene expression in prostate cancer [10] . Chandran et al. analyzed Affymetrix oligonucleotide arrays and their results shows that 415 genes are up-regulated and 364 genes are down-regulated in metastatic prostate tumor [11] . Some studies report genes that are not included in published pathways as cancer-related genes [12] [13] [14] [15] . Thus, researchers must locate the crux of pathways and their environment and apply gene-wide and protein-wide data to find the relationship between those genes and published pathways. Some activated pathways cut across the published pathways from those cancer-related genes that are not emphasized on the published pathways. Therefore, a significant change in gene level is needed, and the character of cancer can match this requirement. Cancer is strongly associated with defects in signal transduction pathways. In cancer tissue, the function of pathways is uncontrolled and inappropriate. When a gene shows a significant change, an activated pathway across this gene allows researchers to infer a pathway from here, even if they do not know which pathway is activated.
Materials and Methods
This study involves the collection of three kinds of data. Protein-protein interaction data is used for network construction. Protein location information prevents an impossible interaction. Finally, gene expression profile reveals the strength of change. All of the proteins/genes used in this study were normalized to a specific symbol using data downloaded from the Uniprot [16] . To construct a PPI network, protein-protein interaction information was collected from the Interologous Interaction Database (I2D) [17] . The data is combined from 6 commonly used PPI databases (BIND, BioGrid, HPRD, INNATEDB, IntAct, and MINT). We filtered out specific PPIs (e.g., experimental or predicted data). The remaining PPIs are non-redundant PPIs and the number exceeds 70,000. To avoid interactions that do not naturally exist, this study follows the basic protein targeting pathways to remove them. It means that all reactions in the results can really happen in cell. The real reactions happen between cytoplasm and nucleus, cytoplasm and mitochondria, cytoplasm and endoplasmic reticulum, cytoplasm and chloroplast, cytoplasm and peroxisome, endoplasmic reticulum and golgi apparatus, lysosome and golgi apparatus, secretory vesicles and golgi apparatus, plasma membrane and golgi apparatus, plasma membrane and secretory vesicles, plasma membrane and endosome, and lysosome and endosome. A change on gene expression is applied to locate pathways on the PPI network. More severe changes are needed, and we collected gene expression data of cancer. Many tumors' gene data samples are available in the GEO data set. This study uses prostate cancer (GDS2545), which is a metastatic prostate tumors and primary prostate tumors (Affymetrix Human Genome U95 Version 2 Array) that includes 12,625 identifiers/genes. That study is that normal tissue adjacent to the tumor and normal donor tissue also examined. Specifically, metastasis reflects the most adverse clinical outcome and provides insight into the molecular mechanisms underlying the metastatic process. This dataset is from 18 donor and 64 primary prostate tumor samples. The stages are divided into four stages. The four stages are "Stage 1: normal prostate tissue", "Stage 2: normal prostate adjacent to tumor", "Stage 3: primary prostate tumor" and "Stage 4: metastatic prostate tumor". According the header description of GDS2545, these samples are divided into three groups: "normal prostate adjacent to tumor versus normal prostate tissue", "primary prostate tumor versus normal prostate adjacent to tumor" and "metastatic prostate tumor versus primary prostate tumor". Next, we used a selfdeveloped tool to analyze these three groups based on a function of R package. less than 0.05, the expression change of a gene between two statuses, original status and developed status, is considered to be significant. A gene with a significant change on gene expression is named as a locating gene/point. This is because one or more activated pathway crosses that point in the developed status. Therefore, we should find fixedsearching-depth fragments of pathway from a locating point. We suggest that an activated pathway could exhibit more severe change than inactivated pathways at the same situation. Thus, the strength of change should be calculated. This study uses a parameter GCS (Gene Expression Change Score) to measure the strength of gene expression change. The GCS equation is defined as follows (1):
here n i is the total interaction number of gene i on the PPI network (non-loops). To decide the strength of edge between gene i and gene k, the score equation is defined as ECS (Edge Change Score) (2):
An ECS is the average of two GCSs in an interaction. When we determine how to measure the strength of edge's change, the strength of pathway fragment's change in a fixed searching depth could be calculated as PCS (Pathway Change Score) (3):
Searching Depth
A PCS is the average of all ECSs in a merged-fragment subnetwork. A searching-depth x of fragment includes x+1 nodes/genes. To rank the PCSs, the highest scores are considered as potential pathway fragments. In the study, we adopt searching-depth 2 because a fragment including at most 5 nodes/genes (length 5) can be created from these results. Results show that every locating point leads to thousands of fragments that include some loops and twoway fragments. All top 5 fragments (non-loops and nonredundancies) were merged into a subnetwork. Merging these subnetworks produces the final results, which is a pathway map. The proposed process involves several scoring and searching steps, as illustrated in Figure 1 .
Results
This study uses prostate cancer data (KEGG pathway map hsa05215 and GEO GDS2545) to develop and test the proposed method. According to the available data, three groups Table 2 shows the locating points on the KEGG prostate cancer map at these three groups. The next step calculates the gene expression change score GCS of each point. To understand which pathway is active, the edge expression change score ECS is defined to score the intensity of change in the link/edge between normal and other situations. The number of pathway fragments that need to be scored depends on the degree of interaction. From the distributions of fragment score, rare fragments that pass the locating points have strong reaction. For merging top-x score fragments, three pathway maps of these groups for prostate cancer are shown in Figure 2 . 
Conclusion
We proposed a heuristic method to measure the change of pathway expression. We pointed out that only PPIs or gene expressions are not enough for pathway inference. This method could solve the problem to integration of proteinprotein interaction and gene expression. A series of computational test was conducted to show that our algorithm could draw pathways maps with stage status and showed the progress of cancer.
As for group A, pathway map in Figure 2 shows the progress from normal to tumor. AURKA, EPRS, HSPA9, MAP3K7, MLST8, NR2C2, and RAF1 appear on the first pathway map. Among these, AURKA, EPRS, MAPK3K7 and RAF1 could be found on the related page of GeneCards.
In the pathway map for group B (see Figure 3 ), CTNNB1 and EGFR could be found on the related page of GeneCards.
In the pathway map for group C (see Figure 4) , AKT1, CREB3L4, CTNNB1, PIK3CG, RAF1, RB1 and SFN) could be found on the related page of GeneCards. It proves these genes are associated with prostate cancer to a certain degree. As for other genes that are not show the association to prostate cancer on the GeneCards, they have to be proved by further works.
Discussion
Via three result pathway maps, different genes play important roles at different disease stages respectively. The number of genes with "significant gene expression change" grows. The direction is from membrane to nuclear. The proposed method integrates gene expression data and protein-protein interactions for pathway research. This approach uses quantitative identification to find the fragments of activated pathways and construct the neighbourhood around known pathways. This study reveals the role and importance of the neighbourhood around cancer pathways. In the global pathway maps the results show the potential relationships of cancer-related genes that do not appear on the known pathway map. These relationships provide a possible approach to find potential and unknown cancer-related genes. The orange ellipses show a node in KEGG prostate cancer pathway map without significant change in gene expression at group B, but a hub for pink ellipses in this map. Figure 4 . The pathway map C for group C. This map shows the situation from primary prostate tumor to metastatic prostate tumor. The pink ellipses show a node in KEGG prostate cancer pathway map with significant change in gene expression at group C. The orange ellipses show a node in KEGG prostate cancer pathway map without significant change in gene expression at group C, but a hub for pink ellipses in this map.
